Fight back with
Felycin®-CA1

(sirolimus delayed-release tablets)

Felycin®-CA1 (sirolimus delayed-release tablets) is the first disease-modifying drug that can give hope to owners of cats with subclinical hypertrophic cardiomyopathy (HCM).

NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE • NOW AVAILABLE •

Meet the first-in-class management for HCM.

Felycin®-CA1 is the first and only FDA conditionally approved once-weekly drug for the management of ventricular hypertrophy in cats with subclinical HCM. Read our detailer to learn more about Felycin-CA1.

download detailer

What does Felycin®-CA1 do?

In a 180-day study, cats treated with the recommended once-weekly label dose of Felycin®-CA1 had a significantly lower maximal heart wall thickness, showing an average reduction of 0.17mm.1

Felycin®-CA1’s mode of action

Felycin®-CA1 Social Media Assets

We know how important client education is, especially when it comes to conditions like hypertrophic cardiomyopathy (HCM) in cats. That’s why we created a set of Felycin®-CA1 social media assets you can easily share from your own veterinary pages.

Use these posts to spark conversations, raise awareness, and keep your clients informed. Want more? Sign up to get notified when new assets are released.

Click here to download

Be First. Be Ready.

Sign up now to be among the first to receive updates related to Felycin-CA1.